John B Dever1,2, Julie H Ducom1, Ariel Ma1, Joseph Nguyen1, Lin Liu2, Ann Herrin1, Erik J Groessl1,2, Samuel B Ho3,4. 1. Medicine, Pharmacy, Nursing, and Research Services, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. 2. University of California, San Diego, CA, USA. 3. Medicine, Pharmacy, Nursing, and Research Services, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. samuel.ho2@va.gov. 4. University of California, San Diego, CA, USA. samuel.ho2@va.gov.
Abstract
BACKGROUND AND AIMS: The extent to which hepatitis C (HCV) treatment uptake is improved following introduction of interferon-free direct-acting antiviral (DAA) treatments is unknown. The purpose of this study was to determine HCV patient engagement and barriers to care for accessing DAA treatments in a real-world setting. METHODS: Patients with HCV viremia at high risk for fibrosis were identified using the Veterans Affairs (VA) registry within San Diego's VA in October 2014. Patients not enrolled in HCV clinic were systematically contacted by letter and phone. Logistic regression was used to examine patient factors associated with subsequent engagement in care over 12-20 months. RESULTS: In the local registry of 2089 patients, 481 were identified with high-risk fibrosis scores. Of those, 380 (79%) were eligible for antiviral treatment, and 178/380 (47%) patients were actively followed in clinic. The remaining 202/380 (53%) patients were never seen by a HCV clinic provider or lost to follow-up. Of these, 114/380 (30%) of the treatment-eligible cohort remained non-engaged in care following outreach. Compared with patients engaged in care, non-engaged patients were significantly more likely to have homelessness, COPD comorbidity, or active alcohol or/and drug use. Overall 74.4% of patients engaged in HCV clinic received antiviral treatment. CONCLUSIONS: A significant portion of eligible HCV patients could not be engaged in treatment after a programmatic outreach effort. These data indicate that more sustained or innovative outreach efforts are needed in order to maximize treatment access, with specific interventions targeting those with unstable housing and active alcohol/substance use disorders.
BACKGROUND AND AIMS: The extent to which hepatitis C (HCV) treatment uptake is improved following introduction of interferon-free direct-acting antiviral (DAA) treatments is unknown. The purpose of this study was to determine HCV patient engagement and barriers to care for accessing DAA treatments in a real-world setting. METHODS:Patients with HCV viremia at high risk for fibrosis were identified using the Veterans Affairs (VA) registry within San Diego's VA in October 2014. Patients not enrolled in HCV clinic were systematically contacted by letter and phone. Logistic regression was used to examine patient factors associated with subsequent engagement in care over 12-20 months. RESULTS: In the local registry of 2089 patients, 481 were identified with high-risk fibrosis scores. Of those, 380 (79%) were eligible for antiviral treatment, and 178/380 (47%) patients were actively followed in clinic. The remaining 202/380 (53%) patients were never seen by a HCV clinic provider or lost to follow-up. Of these, 114/380 (30%) of the treatment-eligible cohort remained non-engaged in care following outreach. Compared with patients engaged in care, non-engaged patients were significantly more likely to have homelessness, COPD comorbidity, or active alcohol or/and drug use. Overall 74.4% of patients engaged in HCV clinic received antiviral treatment. CONCLUSIONS: A significant portion of eligible HCV patients could not be engaged in treatment after a programmatic outreach effort. These data indicate that more sustained or innovative outreach efforts are needed in order to maximize treatment access, with specific interventions targeting those with unstable housing and active alcohol/substance use disorders.
Entities:
Keywords:
Cirrhosis; Direct-acting antivirals; FIB-4; Hepatitis C virus; Linkage to care
Authors: Samuel B Ho; Norbert Bräu; Ramsey Cheung; Lin Liu; Courtney Sanchez; Marisa Sklar; Tyler E Phelps; Sonja G Marcus; Michelene M Wasil; Amelia Tisi; Lia Huynh; Shannon K Robinson; Allen L Gifford; Steven M Asch; Erik J Groessl Journal: Clin Gastroenterol Hepatol Date: 2015-02-24 Impact factor: 11.382
Authors: Lorenzo Moja; Koren H Kwag; Theodore Lytras; Lorenzo Bertizzolo; Linn Brandt; Valentina Pecoraro; Giulio Rigon; Alberto Vaona; Francesca Ruggiero; Massimo Mangia; Alfonso Iorio; Ilkka Kunnamo; Stefanos Bonovas Journal: Am J Public Health Date: 2014-10-16 Impact factor: 9.308
Authors: Shruti H Mehta; David L Thomas; Mark S Sulkowski; Mahboobeh Safaein; David Vlahov; Steffanie A Strathdee Journal: AIDS Date: 2005-10 Impact factor: 4.177
Authors: Omar T Sims; David E Pollio; Barry A Hong; Mamta K Jain; Geri R Brown; Carol S North Journal: Ann Clin Psychiatry Date: 2016-02 Impact factor: 1.567
Authors: Scott D Holmberg; Mei Lu; Loralee B Rupp; Lois E Lamerato; Anne C Moorman; Vinutha Vijayadeva; Joseph A Boscarino; Emily M Henkle; Stuart C Gordon Journal: Clin Infect Dis Date: 2013-04-16 Impact factor: 9.079
Authors: Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley Journal: J Public Health (Oxf) Date: 2019-12-20 Impact factor: 2.341
Authors: Joshua A Blackwell; Joel B Rodgers; Ricardo A Franco; Stacey S Cofield; Lauren A Walter; James W Galbraith; Erik P Hess Journal: Am J Emerg Med Date: 2019-11-29 Impact factor: 2.469